Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Bladder Cancer

Free Subscription 08.08.2022 1 Aging (Albany NY) 1 Am J Clin Pathol 1 Am J Gastroenterol 1 Anticancer Res 1 Biochem Biophys Res Commun 1 Biochem Cell Biol 1 BJU Int 1 BMC Genom Data 2 BMC Urol 1 Cancer Cytopathol 1 Cancer Discov 1 Cancer Gene Ther 1 Cancer Med 1 Clin Cancer Res 9 Curr Opin Urol 1 Diagn Cytopathol 2 Dis Markers 1 Environ Health Perspect 1 Eur J Epidemiol 1 Eur Urol Focus 5 Eur Urol Oncol 1 Front Cell Dev Biol 1 Front Genet 1 Front Immunol 1 Front Mol Biosci 5 Front Oncol 1 Front Pharmacol 1 Front Surg 1 Int J Cancer 1 Int J Med Sci 1 Int J Mol Sci 1 Integr Cancer Ther 1 J Adv Res 1 J Cell Physiol 1 J Clin Lab Anal 1 J Immunol Res 1 J Inflamm Res 1 J Med Imaging Radiat Oncol 1 JCI Insight 1 Med J Malaysia 1 Medicina (B Aires) 2 Pathol Res Pract 1 Scand J Urol 5 Urol Int 1 Urol Oncol 1 Urologie 3 Urology 1 Virchows Arch

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aging (Albany NY)

1. TANG Z, Tang C, Sun C, Ying X, et al
   M1 macrophage-derived exosomes synergistically enhance the anti- bladder cancer effect of gemcitabine.
   Aging (Albany NY). 2022;14.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

2. ZALESKI MP, Chen H, Roy-Chowdhuri S, Patel KP, et al
   Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.
   Am J Clin Pathol. 2022;158:263-269.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

3. OKAMOTO T, Yamamoto K, Kanomata N
   Correction to: Metastatic Rectal Linitis Plastica From Bladder Cancer.
   Am J Gastroenterol. 2022;117:1336.
   PubMed        
   
   

   
   Anticancer Res

4. VASSILIOU V, Katsila T, Sodergren SC, Kardamakis D, et al
   Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications.
   Anticancer Res. 2022;42:3767-3778.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

5. XU Y, Lei Z, Zhu J, Wan L, et al
   Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway.
   Biochem Biophys Res Commun. 2022;623:120-126.
   PubMed         Abstract available
   
   

   
   Biochem Cell Biol

6. LIU T, Zhang Z, Wang C, Huang H, et al
   Correction: BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance.
   Biochem Cell Biol. 2022;100:274-275.
   PubMed        
   
   

   
   BJU Int

7. JAMES ND, Liu W, Pirrie S, Kaur B, et al
   TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer.
   BJU Int. 2022 Jul 31. doi: 10.1111/bju.15864.
   PubMed         Abstract available
   
   

   
   BMC Genom Data

8. ZHU Q, Zhang L, Deng Y, Tang L, et al
   Identification of immune-related and autophagy-related genes for the prediction of survival in bladder cancer.
   BMC Genom Data. 2022;23:60.
   PubMed         Abstract available
   
   

   
   BMC Urol

9. XIANG AP, Chen XN, Xu PF, Shao SH, et al
   Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma.
   BMC Urol. 2022;22:120.
   PubMed         Abstract available
   
   
10. WANG J, Tuo Z, Gao M, Min J, et al
    Is it necessary to perform a retrosigmoid transposition of the left ureter in Bricker Ileal Conduit surgery?
    BMC Urol. 2022;22:116.
    PubMed         Abstract available
    
    

    
    Cancer Cytopathol

11. KIM D, Burkhardt R, Alperstein SA, Gokozan HN, et al
    Evaluating the role of Z-stack to improve the morphologic evaluation of urine cytology whole slide images for high-grade urothelial carcinoma: Results and review of a pilot study.
    Cancer Cytopathol. 2022;130:630-639.
    PubMed         Abstract available
    
    

    
    Cancer Discov

12. GOUBET AG, Lordello L, Alves Costa Silva C, Peguillet I, et al
    Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer.
    Cancer Discov. 2022 Aug 5. pii: 707463. doi: 10.1158/2159-8290.CD-22-0201.
    PubMed         Abstract available
    
    

    
    Cancer Gene Ther

13. LIU Q, You B, Meng J, Huang CP, et al
    Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.
    Cancer Gene Ther. 2022 Aug 1. pii: 10.1038/s41417-022-00506.
    PubMed         Abstract available
    
    

    
    Cancer Med

14. KARASHIMA T, Umemoto S, Kishida T, Osaka K, et al
    Clinical evaluation of urine laminin-gamma2 monomer as a potent biomarker for non-muscle invasive bladder cancer.
    Cancer Med. 2022 Aug 4. doi: 10.1002/cam4.5087.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

15. ZHU Z, Ma AH, Zhang H, Lin TY, et al
    Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer.
    Clin Cancer Res. 2022 Aug 3. pii: 707432. doi: 10.1158/1078-0432.CCR-22-1362.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

16. ESCOTT M, Avulova S, Bree KK, Westerman ME, et al
    Radical cystectomy and women's sexual health - can we do better?
    Curr Opin Urol. 2022;32:545-553.
    PubMed         Abstract available
    
    
17. PIJPERS OM, de Jong JJ, Zuiverloon TCM, Boormans JL, et al
    RNA-based urinary assays for non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022;32:523-530.
    PubMed         Abstract available
    
    
18. COMPERAT E, Oszwald A, Wasinger G, Klager J, et al
    Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis.
    Curr Opin Urol. 2022;32:451-455.
    PubMed         Abstract available
    
    
19. LAUKHTINA E, Pradere B, Lemberger U, Karakiewicz PI, et al
    Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder.
    Curr Opin Urol. 2022;32:561-566.
    PubMed         Abstract available
    
    
20. SHEYBAEE MOGHADDAM F, Ghoreifi A, Djaladat H
    Comparative performance of the different orthotopic urinary diversions.
    Curr Opin Urol. 2022;32:554-560.
    PubMed         Abstract available
    
    
21. KIM SH, Lerner SP
    Drug instillation in the management of urinary tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:531-535.
    PubMed         Abstract available
    
    
22. MESSINA E, Pisciotti ML, Pecoraro M, Borrelli A, et al
    The use of MRI in urothelial carcinoma.
    Curr Opin Urol. 2022;32:536-544.
    PubMed         Abstract available
    
    
23. COMPERAT E, Wasinger G, Oszwald A, Shariat SF, et al
    Brief update of the new WHO classification for urothelial carcinoma.
    Curr Opin Urol. 2022;32:511-516.
    PubMed         Abstract available
    
    
24. MARTINI A, Fallara G, Ploussard G, Pradere B, et al
    Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma.
    Curr Opin Urol. 2022;32:500-503.
    PubMed         Abstract available
    
    

    
    Diagn Cytopathol

25. WANG BG, Woodward K, Menezes G, Wang ZQ, et al
    Pleural fluid metastasis of plasmacytoid urothelial carcinoma in comparison to micropapillary and conventional high-grade urothelial carcinoma: Cytologic and immuonohistochemical findings.
    Diagn Cytopathol. 2022;50:E248-E254.
    PubMed         Abstract available
    
    

    
    Dis Markers

26. ZHAO X, Hu J, Li J, Gu L, et al
    THEM6: A Novel Molecular Biomarker Predicts Tumor Microenvironment, Molecular Subtype, and Prognosis in Bladder Cancer.
    Dis Markers. 2022;2022:7147279.
    PubMed         Abstract available
    
    
27. HE L, Yang B, Jian D, Luo H, et al
    Prognostic Value of HPV E6 and APOBEC3B in Upper Urinary Tract Urothelial Carcinoma.
    Dis Markers. 2022;2022:2147494.
    PubMed         Abstract available
    
    

    
    Environ Health Perspect

28. WEISMAN RJ, Heinrich A, Letkiewicz F, Messner M, et al
    Estimating National Exposures and Potential Bladder Cancer Cases Associated with Chlorination DBPs in U.S. Drinking Water.
    Environ Health Perspect. 2022;130:87002.
    PubMed         Abstract available
    
    

    
    Eur J Epidemiol

29. COSCIA C, Gill D, Benitez R, Perez T, et al
    Avoiding collider bias in Mendelian randomization when performing stratified analyses.
    Eur J Epidemiol. 2022;37:671-682.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

30. KIM YS, Hsieh AC, Lam HM
    Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery.
    Eur Urol Focus. 2022 Jul 29. pii: S2405-4569(22)00166.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

31. GALLIOLI A, Diana P, Fontana M, Territo A, et al
    En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial.
    Eur Urol Oncol. 2022;5:440-448.
    PubMed         Abstract available
    
    
32. LENFANT L, Breda A, Xylinas E, Babjuk M, et al
    Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma.
    Eur Urol Oncol. 2022;5:464-471.
    PubMed         Abstract available
    
    
33. SORIA F, Gontero P
    Intermediate-risk Non-muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?
    Eur Urol Oncol. 2022 Jul 27. pii: S2588-9311(22)00115.
    PubMed        
    
    
34. STENZL A
    En Bloc Resection of Bladder Tumours: Ready for Clinical Use?
    Eur Urol Oncol. 2022;5:449-450.
    PubMed        
    
    
35. MARTINI A, Lonati C, Nocera L, Fallara G, et al
    Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma.
    Eur Urol Oncol. 2022;5:451-459.
    PubMed         Abstract available
    
    

    
    Front Cell Dev Biol

36. TAN J, Wang Y, Sun L, Xu S, et al
    The Origin and Evolution of Bladder Cancer Stem Cells.
    Front Cell Dev Biol. 2022;10:950241.
    PubMed         Abstract available
    
    

    
    Front Genet

37. TANG D, Li Y, Tang Y, Zheng H, et al
    Recognition of Glycometabolism-Associated lncRNAs as Prognosis Markers for Bladder Cancer by an Innovative Prediction Model.
    Front Genet. 2022;13:918705.
    PubMed         Abstract available
    
    

    
    Front Immunol

38. OU SL, Luo J, Wei H, Qin XL, et al
    Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.
    Front Immunol. 2022;13:953761.
    PubMed         Abstract available
    
    

    
    Front Mol Biosci

39. SU Z, Monshaugen I, Klungland A, Ougland R, et al
    Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow.
    Front Mol Biosci. 2022;9:887686.
    PubMed         Abstract available
    
    

    
    Front Oncol

40. ZHANG Z, Li X, Ren S, Zhang W, et al
    CNN1 Represses Bladder Cancer Progression and Metabolic Reprogramming by Modulating HIF-1alpha Signaling Pathway.
    Front Oncol. 2022;12:859707.
    PubMed         Abstract available
    
    
41. LI DX, Wang XM, Feng DC, Zhang FC, et al
    Lymphocyte-to-Monocyte Ratio (LMR) During Induction Is a Better Predictor Than Preoperative LMR in Patients Receiving Intravesical Bacillus Calmette -Guerin for Non-Muscle-Invasive Bladder Cancer.
    Front Oncol. 2022;12:937638.
    PubMed         Abstract available
    
    
42. CHENG X, Lou K, Ding L, Zou X, et al
    Clinical potential of the Hippo-YAP pathway in bladder cancer.
    Front Oncol. 2022;12:925278.
    PubMed         Abstract available
    
    
43. ZHU Z, Xiao Y, Hu S, Wang Z, et al
    Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis.
    Front Oncol. 2022;12:907454.
    PubMed         Abstract available
    
    
44. CHEN T, Zhan X, Chen X, Jiang M, et al
    Predictive Value of the Log Odds of Negative Lymph Nodes/T Stage as a Novel Prognostic Factor in Bladder Cancer Patients After Radical Cystectomy.
    Front Oncol. 2022;12:895413.
    PubMed         Abstract available
    
    

    
    Front Pharmacol

45. CHENG Z, Ye F, Xu C, Liang Y, et al
    The potential mechanism of Longsheyangquan Decoction on the treatment of bladder cancer: Systemic network pharmacology and molecular docking.
    Front Pharmacol. 2022;13:932039.
    PubMed         Abstract available
    
    

    
    Front Surg

46. GUO M, Li Y, Wang W, Kang X, et al
    Variation of Anxiety and Depression During a 3-Year Period as Well as Their Risk Factors and Prognostic Value in Postoperative Bladder Cancer Patients.
    Front Surg. 2022;9:893249.
    PubMed         Abstract available
    
    

    
    Int J Cancer

47. XIONG J, Yang L, Deng YQ, Yan SY, et al
    The causal association between smoking, alcohol consumption and risk of bladder cancer: A univariable and multivariable Mendelian randomization study.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34228.
    PubMed         Abstract available
    
    

    
    Int J Med Sci

48. CHOI NR, Choi WG, Kwon MJ, Woo JH, et al
    [6]-Gingerol induces Caspase-Dependent Apoptosis in Bladder Cancer cells via MAPK and ROS Signaling.
    Int J Med Sci. 2022;19:1093-1102.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

49. MONTES-MOJARRO IA, Hassas S, Staehle S, Sander P, et al
    Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available
    
    

    
    Integr Cancer Ther

50. HWANG B, Gho Y, Kim H, Lee S, et al
    Rosa hybrida Petal Extract Exhibits Antitumor Effects by Abrogating Tumor Progression and Angiogenesis in Bladder Cancer Both In Vivo and In Vitro.
    Integr Cancer Ther. 2022;21:15347354221114337.
    PubMed         Abstract available
    
    

    
    J Adv Res

51. GELBRICH N, Miebach L, Berner J, Freund E, et al
    Non-invasive medical gas plasma augments bladder cancer cell toxicity in preclinical models and patient-derived tumor tissues.
    J Adv Res. 2022 Aug 2. pii: S2090-1232(22)00166.
    PubMed         Abstract available
    
    

    
    J Cell Physiol

52. TSAI TF, Chang AC, Chen PC, Ho CY, et al
    Autophagy blockade potentiates cancer-associated immunosuppression through programmed death ligand-1 upregulation in bladder cancer.
    J Cell Physiol. 2022 Jul 29. doi: 10.1002/jcp.30817.
    PubMed         Abstract available
    
    

    
    J Clin Lab Anal

53. SETTI BOUBAKER N, Gurtner A, Trabelsi N, Manni I, et al
    An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer.
    J Clin Lab Anal. 2022 Jul 19:e24606. doi: 10.1002/jcla.24606.
    PubMed         Abstract available
    
    

    
    J Immunol Res

54. LUO H, Liu GL, Jian D, Liang DD, et al
    Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade.
    J Immunol Res. 2022;2022:9962397.
    PubMed         Abstract available
    
    

    
    J Inflamm Res

55. GAO M, Yang Q, Xu H, Chen Z, et al
    Preoperative White Blood Cell-Related Indicators Can Predict the Prognosis of Patients with Transurethral Resection of Bladder Cancer.
    J Inflamm Res. 2022;15:4139-4147.
    PubMed         Abstract available
    
    

    
    J Med Imaging Radiat Oncol

56. FERNANDES MC, Shoushtari A, Leitao MM Jr, Chui MH, et al
    Metastatic melanoma concurrent to the urinary bladder and endometrium: Case report.
    J Med Imaging Radiat Oncol. 2022;66:643-646.
    PubMed         Abstract available
    
    

    
    JCI Insight

57. REHMAN H, Chandrashekar DS, Balabhadrapatruni C, Nepal S, et al
    ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.
    JCI Insight. 2022 Jul 19. pii: 155899. doi: 10.1172/jci.insight.155899.
    PubMed         Abstract available
    
    

    
    Med J Malaysia

58. RINONCE HT, Ambarwati THD, Syaebani M, Pudjohartono MF, et al
    Assessment of association between PD-L1 expression and clinicopathological characteristics of Indonesian patients with high grade bladder urothelial carcinoma.
    Med J Malaysia. 2022;77.
    PubMed         Abstract available
    
    

    
    Medicina (B Aires)

59. NAZAR M, Sabatella A, Ficalora G, Troncoso Y, et al
    [Rectal metastasis of a resected urothelial bladder cancer].
    Medicina (B Aires). 2022;82:609-612.
    PubMed         Abstract available
    
    

    
    Pathol Res Pract

60. MARCHESE PV, Mollica V, De Biase D, Giunchi F, et al
    A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
    Pathol Res Pract. 2022;236:153983.
    PubMed         Abstract available
    
    
61. LEDDEROSE S, Rodler S, Eismann L, Ledderose G, et al
    Tumor-infiltrating lymphocytes predict survival in >/= pT2 urothelial bladder cancer.
    Pathol Res Pract. 2022;237:154037.
    PubMed         Abstract available
    
    

    
    Scand J Urol

62. MAY M, Wolff I, Brookman-May SD, Burger M, et al
    Bladder cancer with secondary muscle invasion - a prognostic dilemma.
    Scand J Urol. 2022 Aug 3:1-2. doi: 10.1080/21681805.2022.2107068.
    PubMed        
    
    

    
    Urol Int

63. STOKKEL LE, van de Kamp MW, Schaake EE, Boellaard TN, et al
    Robot-Assisted Partial Cystectomy versus Open Partial Cystectomy for Patients with Urachal Cancer.
    Urol Int. 2022;106:840-847.
    PubMed         Abstract available
    
    
64. NIENTIEDT M, Waldbillig F, Stroop F, Nuhn P, et al
    Upper Tract Urinary Cancer Recurrence after Radical Cystectomy: Risk Assessment of Intraoperative Frozen Section.
    Urol Int. 2022;106:816-824.
    PubMed         Abstract available
    
    
65. DREGER NM, Lohbeck A, Roth S, Godde D, et al
    Effectiveness and Safety of a Modified Technique of Transvesical Obturator Nerve Block to Avoid Adductor Contractions during Transurethral Resection of Bladder Tumors.
    Urol Int. 2022;106:775-783.
    PubMed         Abstract available
    
    
66. SCHNEIDEWIND L, Torabi L, Drager DL, Hakenberg OW, et al
    Reduction of Perioperative Antibiotic Prophylaxis in Open Radical Cystectomy with Ileal Conduit Is Feasible: Results of a Prospective Clinical Trial.
    Urol Int. 2022;106:825-831.
    PubMed         Abstract available
    
    
67. CILESIZ NC, Ozkan A, Kalkanli A, Gezmis CT, et al
    Spinal Anesthesia Provides Longer Administration Time for Postoperative Intravesical Chemotherapy after TUR-B Operation.
    Urol Int. 2022;106:768-774.
    PubMed         Abstract available
    
    

    
    Urol Oncol

68. KRAJEWSKI W, Aumatell J, Subiela JD, Nowak L, et al
    Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
    Urol Oncol. 2022 Jul 15. pii: S1078-1439(22)00227.
    PubMed         Abstract available
    
    

    
    Urologie

69. GUZVIC M, Engelmann S, Burger M, Mayr R, et al
    [Disseminated tumour cells in bladder cancer].
    Urologie. 2022;61:728-733.
    PubMed         Abstract available
    
    

    
    Urology

70. ELSAYED AS, Iqbal U, Jing Z, Houenstein HA, et al
    Relapses Rates and Patterns for Pathological T0 After Robot-Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium.
    Urology. 2022;166:177-181.
    PubMed         Abstract available
    
    
71. MITCHELL K, Elbakry AA, Naili RE, Al-Omar O, et al
    Dysfunctional Voiding- Presentation of a Rare Case of Pediatric Non Muscle Invasive Urothelial Bladder Carcinoma.
    Urology. 2022;166:233-235.
    PubMed         Abstract available
    
    
72. SHUMAKER L, Nocera A, Selph P
    Enhanced Recovery After Surgery in the Urinary Diversion Population: Are Protocols Applied Differently in the Benign Indication Population?
    Urology. 2022;166:50-55.
    PubMed         Abstract available
    
    

    
    Virchows Arch

73. QUEIPO FJ, Unamunzaga GM, Negro BF, Fuertes SG, et al
    Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
    Virchows Arch. 2022;481:191-200.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: